Skip to main content
Insights into Imaging

Table 1 Characters of patients in the training and test cohorts

From: CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn’s disease resistant to infliximab

 

Training cohort (n = 112)

Test cohort 1 (n = 48)

Test cohort 2 (n = 71)

Characters

Response (n = 79)

PNR (n = 33)

p value

Response (n = 34)

PNR (n = 14)

p value

Response (n = 49)

PNR (n = 22)

p value

Agea

25.0 (9–56)

24.2 (12–41)

0.434

25 (14–49)

22 (14-46)

0.220

26 (16–39)

24 (13–50)

0.910

Sexb

  

0.983

  

0.320

  

0.999

 Male

58 (73.4%)

25 (75.8%)

 

27 (74%)

8 (57%)

 

44 (90%)

15 (68%)

 

 Female

21 (26.6%)

8 (24.2%)

 

9 (26%)

6 (43%)

 

5 (10%)

7 (32%)

 

BMI (kg/m2)c

18.3 ± 2.6

17.2 ± 2.6

0.058

18.4 ± 2.9

17.1 ± 2.0

0. 081

20.1 ± 2.9

18.9 ± 3.1

0.087

CRP (mg/L)c

26.2 ± 25.8

37.6 ± 30.6

0.065

33.8 ± 28.3

47.9 ± 28.1

0.100

28.6 ± 30.5

35.1 ± 32.0

0.180

ESR (mm/h)c

50.4 ± 26.9

57.0 ± 30.4

0.283

57.4 ± 32.4

73.2 ± 35.0

0.140

38.6 ± 25.3

54.7 ± 30.2

0.039*

Hb (g/L)c

111.8 ± 17.8

102.1 ± 17.5

0.004*

107.3 ± 24.7

105.6 ± 12.4

0.360

99.4 ± 14.8

140.3± 17.3

0.140

ALB (g/L)c

34.8 ± 4.9

30.8 ± 4.9

< 0.001*

33.3 ± 6.1

33.7 ± 4.3

0.950

39.5 ± 9.2

35.6 ± 5.3

0.032*

PLT (103/mm3)a

357 (137–604)

407 (283–491)

0.057

444 (147–808)

376 (115–763)

0.092

355 (145–701)

408 (226–742)

0.190

Disease behaviorb

         

 B1 (inflammatory)d

45 (57.0%)

13 (39.4%)

 

18 (53%)

7 (50%)

0.691 

40 (82%)

17 (77%)

0.865

 B2 (stricturing)d

25 (31.6%)

15 (45.5%)

 

12 (35%)

5 (36%)

0.794

1 (2.0%)

1 (4.5%)

0.999

 B3 (penetrating)d

9 (11.4%)

5 (15.1%)

 

4 (12%)

2 (14%)

0.999

8 (16%)

4 (18%)

0.999

Perianal diseased

9 (11.4%)

6 (18.2%)

 

4 (12%)

2 (14%)

0.990

31 (63%)

11 (50%)

0.290

Disease locationb

  

0.362

  

0.347

  

0.760

 L1 (ileal disease)

13 (16.5%)

2 (6.1%)

 

4 (12%)

3 (21%)

 

8 (16%)

2 (9.1%)

 

 L2 (colonic disease)

6 (7.6%)

3 (9.1%)

 

0 (0%)

2 (14%)

 

5 (10%)

3 (14%)

 

 L3 (ileocolonic disease)

60 (75.9%)

28 (84.8%)

 

30 (88%)

9 (64%)

 

36 (73%)

17 (77%)

 

Duration of diseaseb

  

0.495

  

0.754

  

0.360

 (< 2 years)

50 (63.3%)

16 (48.5%)

 

23 (68%)

10 (71%)

 

24 (49%)

9 (41%)

 

 (2–5 years)

14 (17.7%)

8 (24.2%)

 

10 (29%)

3 (21%)

 

12 (24%)

9 (41%)

 

 (> 5 years)

15 (19.0%)

9 (27.3%)

 

1 (2.9%)

1 (7.1%)

 

13 (27%)

4 (18%)

 

Medicationsb

         

 Immunomodulator

18 (22.8%)

13 (39.4%)

0.119

5 (15%)

2 (14%)

0.679

25 (51%)

10 (45%)

0.660

 Corticosteroids

10 (12.7%)

5 (15.2%)

0.764

5 (15%)

2 (14%)

0.999

12 (24%)

4 (18%)

0.347

 Aminosalicylates (5‐ASAs)

31 (39.2%)

20 (60.6%)

0.063

13 (38%)

2 (14%)

0.177

29 (59%)

11 (50%)

0.298

 Combination immunosuppression

34 (43.0%)

14 (42.4%)

0.401

16 (47%)

4 (29%)

0.361

21 (43%)

6 (27%)

0.210

CDAIc

219 ± 81.5

246 ± 65.9

-

228 ± 64

265 ± 95

-

251 ± 72

273 ± 66

-

SES‐CDa

16.1 (4–41)

17.2 (0–41)

-

17 (3–31)

13 (0–28)

-

17 (7–30)

20 (9–34)

-

  1. Abbreviations: ALB albumin, BMI body mass index, CDAI Crohn's Disease Activity Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb Hemoglobin, PLT platelets, PNR primary nonresponse, SES‐CD Simple Endoscopic Score for Crohn Disease
  2. aNonnormally distributed continuous variables, expressed as median (interquartile range), line Mann–Whitney U test
  3. bCategorical variables, expressed as frequencies (proportions), line χ2 test
  4. cNormally distributed continuous variables, expressed as mean ± standard deviation, line independent t test
  5. dThe sum of the subgroups does not equal with the total cohort, due to overlapping of B1 and B2 categories. The p value was calculated based on each subgroup
  6. *p value was derived from the univariable association analyses between each characteristic and response/nonresponse status
Back to article page